Antibiotic use for fever after cancer treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how antibiotics are used in the emergency department for patients who may have a low white blood cell count (neutropenic fever) after cancer treatment. The goal is to ensure antibiotics are used appropriately and effectively without causing harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had a fever (temperature 38.3°C or higher) within 24 hours before arriving at the emergency department.
- You must have had chemotherapy or targeted therapy for a solid tumor within the last 6 weeks, or treatment for certain blood cancers (like leukemia or lymphoma), bone marrow disorders, or a stem cell transplant at any time in the past.
- You must be willing to allow the researchers to access your medical records for follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This study looks at how long antibiotics should be given to cancer patients with fever and very low white blood cell counts after finding a certain type of bacteria (Gram-negative) in their blood. The goal is to find the best treatment duration to help patients recover without complications.
This trial tests whether it is safe to stop antibiotics earlier than usual in patients with a low white blood cell count (neutropenia) who have had a fever but have been fever-free for 48 hours. The goal is to reduce unnecessary antibiotic use and its side effects.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
This trial compares stopping antibiotics early (after fever resolves) versus continuing them as usual in adults with blood cancers who develop fever during treatment. It aims to find the best timing to reduce unnecessary antibiotic use.
Hear when a new Neutropenic Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.